Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved

'Unequivocal Benefit' Unveiled At ESC

Executive Summary

The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.

You may also be interested in...



AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data

AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.

Boehringer Pharma Chief Confident Of Continued Success For Jardiance

Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.

After Jardiance Heart Failure Successes, BI And Lilly Focus On Kidney

Jardiance, the best-selling SGLT2 inhibitor, has AstraZeneca’s same-class rival Farxiga firmly in its sights in renal disease after showing such a level of efficacy that the 6,600-patient EMPA-KIDNEY study has been halted.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel